Please assess the completion status of the following clinical trial:

Trial Title: First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 18 and ≤ 75 years old.~2. Symptomatic, recurrent paroxysmal AF lasting \> 30 seconds (at least 4 episodes within the prior 6 months). At least one episode must be documented by Holter,12-lead ECG, event monitor or rhythm strip.~Exclusion Criteria:~1. Documented LVEF \<40%.~2. Documented left atrial diameter \>5.5cm.~3. Moderate to severe LVH (LV wall thickness \>1.5cm).~4. Documented valvular disease, coronary heart disease (defined as the presence of \>70% stenosis of coronary arteries or documentation of active myocardial ischemia), post-CABG, postoperative cardiac surgery or peripheral artery disease.~5. Documented AF with electrical cardioversion where full therapeutic antiarrhythmic drug therapy after the cardioversion was prescribed.~6. Untreated hypothyroidism or hyperthyroidism. Patients who are euthyroid on thyroid hormone replacement therapy are acceptable.~7. Contraindication for the use of sotalol, dofetilide and 1C antiarrhythmic drugs(liver enzymes and serum creatinine that are outside the upper normal lab values, e.g. \> 3 times ULN with 2 abnormal lab values).~8. Previous left heart ablation procedure, either by surgery or by percutaneous catheter, for atrial fibrillation.~9. Current enrollment in another investigational drug or device study.~10. Presence of any other condition that the investigator feels would be problematic or would restrict or limit the participation of the Patient for the entire study period.~11. Absolute contra-indication to the use of heparin and or warfarin.~12. Increase risk of bleeding, current peptic ulceration, proliferative diabetic retinopathy, history of severe systemic bleeding, or other history of bleeding diathesis or coagulopathy.~13. Severe pulmonary disease e.g. restrictive pulmonary disease, chronic obstructive disease (COPD).~14. Documented intra-atrial thrombus, tumor, or another abnormality which precludes catheter introduction.~15. Previous use of full therapeutic dose of an antiarrhythmic drug, including amiodarone, propafenone, flecainide, sotalol, quinidine.~16. Pacemaker or Implantable Cardioverter Defibrillator.~17. Women with a positive pregnancy test.~18. Evidence of active cardiac or systemic infection.~19. Medical condition limiting expected survival to less than one year.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Catheter Ablation (Type: EXPERIMENTAL): Pulmonary vein isolation performed by catheter ablation for the prevention of recurrence of symptomatic atrial fibrillation
- Antiarrhythmic Drug Therapy (Type: ACTIVE_COMPARATOR): Conventional antiarrythmic drug therapy for the prevention of recurrence of symptomatic atrial fibrillation

Based on this trial design, predict the completion outcome and termination type (if applicable).